SH Translational Imaging Innovations Related Content
Degenerative eye disease and the opportunities of ophthalmic drug development
Eric Buckland of Translational Imaging Innovations looks at ophthalmic drug development and how better clinical endpoints can improve success rates.
Clinical Endpoints and data management in the era of ophthalmic precision medicine
Eric Buckland of Translational Imaging Innovations and Ronald Schuchard, Clinical Product Development Expert, explore the benefits of ophthalmic precision medicine to improve patient care across sectors.
Data capture for researching degenerative eye disease
Translational Imaging Innovations makes data accessible to research degenerative eye disease.
The global cost of visual impairment
250 million people suffer from visual impairment at a global cost of $3 trillion, Translational Imaging Innovations explain.
